Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) indication: the treatment of adult and pediatric patients with hereditary tyrosinemia type-1 in combination with a dietary restriction of tyrosine and phenylalanine

The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (Orfadin) be reimbursed for the treatment of adult and pediatric patients with hereditary tyrosinemia type-1 in combination with dietary combination with dietary restriction of tyrosine and phenylalanine, if the following cri...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, February 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Tyrosinemias / Diet Therapy
Insurance, Health, Reimbursement
Canada
Nitrobenzoates / Economics
Tyrosinemias / Drug Therapy
Drug Costs
Nitrobenzoates / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (Orfadin) be reimbursed for the treatment of adult and pediatric patients with hereditary tyrosinemia type-1 in combination with dietary combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met. For use in patients with an established diagnosis of hereditary tyrosinemia type-1. The drug is prescribed by a physician with experience in the diagnosis and management of hereditary tyrosinemia type-1. Price reduction of at least 74%
Item Description:"Final."
Physical Description:1 PDF file (8 pages)

Similar Items